

Evaluation of sister chromatid exchange in patients with breast cancer in relation to clinical stage

Zafir Hassan Ghali

Department of biology /College of Science/University of Wassit –Iraq

تقييم التبادل الكروماتيدي الشقيقي بين مريضات سرطان الثدي وعلاقته مع المرحلة السريرية

ظافر حسن غالي

قسم علوم الحياة –كلية العلوم –جامعة واسط-العراق

الخلاصة

تعكس المستويات العالية للتبادل الكروماتيدي الشقيقي في مريضات سرطان الثدي عدم الثبات الجيني الذي يكون فعال في عملية التسرطن. درس تردد التبادل الكروماتيدي الشقيقي في لمفاويات الدم المحيطي لمريضات سرطان الثدي وعلاقته مع المرحلة السريرية لهذا النوع من السرطان. أجريت الدراسة على ١٢ مريضة مصابة بسرطان الثدي في المرحلة السريرية الثانية للمرض و ٥ مريضات مصابات بالمرض نفسه في المرحلة السريرية الرابعة. قورنت القيم الأساسية للتبادل الكروماتيدي الشقيقي مع مجموعة التحكم التي تتكون من ١٢ من الإناث السليمات. كان الفرق معنويًا عاليًا عند مقارنة المريضات قيد الدراسة مع مجموعة التحكم ($P < 0.01$). وازداد التبادل الكروماتيدي الشقيقي بصورة معنوية في مريضات المرحلة السريرية الرابعة عند مقارنتها بنظيراتها في مريضات المرحلة السريرية الثانية ($P < 0.05$). تُظهر نتائج هذه الدراسة زيادة في تردد التبادل الكروماتيدي الشقيقي مع تقدم الحالة السريرية لسرطان الثدي.

Abstract

High levels of sister chromatid exchanges (SCE) in patients with breast cancer reflects a genomic instability that may be operative in carcinogenesis. The frequency of sister chromatid exchanges in peripheral blood lymphocytes was analyzed in patients with breast cancer in relation to clinical stage in 12 stage II and 5 Stage IV untreated breast cancer patients. Moreover, SCE baseline values in patients were compared with a control group of 12 healthy women. A significant difference emerged between patients and control ($P < 0.01$). SCE increased significantly in stage IV breast cancer patients compared with those patients of stage II ($P < 0.05$). The results reveal that SCE frequency increases with the progression of clinical stage of breast cancer.

Introduction

Breast cancer dramatically impact the lives of affected women and further place a significant economic burden on both their families and the health care system(1).Sister chromatid exchange(SCE) can be used as a preclinical marker for early detection of cancer (2,3).High levels of SCE in breast cancer patients reflect a genomic instability that may be operative in carcinogenesis (4).In this study, the frequency of SCE was analyzed in patients with breast cancer in relation to disease stage.

Materials and Methods

Twelve untreated breast cancer patients in stage II (age:30-65years) and five untreated breast cancer patients stage IV (age: 32-60years) ,in addition to twelve healthy women (age:26-82)as a control were the subjects of this study. Patients were admitted to Baghdad teaching hospital and their clinical stages were determined according TMN system. The samples collected during summer 2008. .Whole blood was cultured in RPMI-1640 medium for SCE analysis.0.25ml of heparinized blood was inoculated in 2ml of RPMI-1640 medium (Serva) containing phytohemagglutinin (PHA) and 10% fetal calf serum (Sigma).Cultures were incubated at 37 for 72 hours .Colchicine 0.1ml (Serva) was added to each culture tube for the final two hours of incubation to harvest the cells. Cells then treated with hypotonic solution (0.075 KCl) for 20 minutes and fixed with methanol-acetic acid (3:1 vol/vol).Cells were dropped onto clean slides (5).SCE were scored using fluorescence plus Giemsa modified staining technique(6).SCE were scored in 25 well-spread second metaphase. Results were analyzed statistically using t-test.

Results and Discussion

Table 1 shows SCE (mean $\pm$ SE) of this study. The frequency of SCE in stage II and stage IV breast cancer patients revealed marked increase in their cells. The mean of SCE was higher in lymphocytes of stage II patients(5.62 ± 0.89 SCE/cell versus 3.12 ± 0.15 in control $P < 0.01$).The mean of SEC of stage IV patients showed high significant value compared with control (6.89 ± 0.87 SCE/cell versus 3.12 ± 0.15 $P < 0.01$).

Table 1:SCE (mean $\pm$ SE) in stage II ,Stage IV and control groups.

Study groups	SCE(Mean $\pm$ SE)
Control	3.12 $\pm$ 0.15
StageII	5.62 $\pm$ 0.89 ^a
StageIV	6.89 $\pm$ 0.87 ^{a, b}

^a P<0.01 vs. control group

^b P<0.05 vs. stage II group

High levels of SCE in those patients reflects impairment of DNA systems and repair (7).Furthermore,BRCA1 and BRCA2 play important roles in the mechanisms that lead to the repair of DNA -double strand breaks (8).Thus, those patients may have mutated BRCA genes.

The results of this study reveal an increase in SCE/cell in patients with breast cancer with progression of disease. The SCE in stage IV patients was higher than SCE in patients with stage II disease. The significance difference was not highly (P<0.05), this may be due to the sample size. Our results were in agreement with Aristei et al.,2009 that their results showed increase in SCE frequency in 20 stage II breast cancer patients.

According to the results of this study ,we conclude that SCE levels increase with progression of clinical stage of breast cancer.

References

- 1.Skibbens,R.V.(2008);Cell biology of cancer-BRCA1 and sister chromatid pairing reactions. Cell Cycle,4:449-452.
2. Mitra, A.B., Murty, V.V.V.S., and Luthra, U.K., (1983): Sisterchromatid exchange in leukocytes of patients with cancer of cervix. Uteri.Hum. Genet., 60:214-215.
3. Skolnick, M., Livingston, G.K., Fineman, R.M., Johnson, P., King, M.C., McIllellan, T., and Bishop, D.P. (1980): Genetics of breast cancergenoclonogical clusters. Major genes linkage and sister chromatid exchange as a preclinical marker. Am.J.Hum.Genet., 32:455-457.

4. Ceflea, K., Ucura, A., Guneyb, N., Ozturca, S., Palanduza, S., Tasb, F., Asogluc, O., Bayraka, A., Muslumanogluc, M., and Aydinerb, a. (2006): Sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives.
5. Ghali, Z.H., Ahmed, I.H. and Ahmed, I.H. (2009): Methotrexate-resistance is associated with double minute chromosomes in lymphocytes from prostate cancer patients. *Wassit Journal for Science and Medicine*. 2:214-220.
6. Benn, P. A., and Perle, M. A. (1992): Chromosome staining and banding technique. In: *Human cytogenetics Vol.I: Constitutional analysis: a practical approach*. Rooney, D. E., and Czepulkowski, B. H. (Eds). Oxford University Press, pp. 90-117.
7. Venkitaraman, A.R. (2001): Functional of BRCA1 and BRCA2 in the biological responded DNA damage. *J. Cell. Sci.*, 114: 3591-3598.
8. Aristei Cynthia; Stracci Fabrizio; Guerrieri Paola; Anselmo Paola; Armellini Rossana; Rulli Antonio; Barberini Francesco; Latini Paolo; Menghini Anna Rita (2009): Frequency of sister chromatid exchanges and micronuclei monitored over time in patients with early-stage breast cancer: results of an observational study. *Cancer genetics and cytogenetics* ;192:24-9.

Recived (9/6 /2010)

Accepted (24/8/2010)